Literature DB >> 21686697

Hydroxychloroquine: a diabetic drug in disguise?

Lydia Kang1, Ted R Mikuls, James R O'Dell.   

Abstract

Hydroxychloroquine (HCQ) is an antimalarial agent that is commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The present report documents a case of hypoglycaemia due to HCQ in a patient with SLE and diabetes mellitus type 2, in which the HCQ completely replaced the need for daily subcutaneous insulin.

Entities:  

Year:  2009        PMID： 21686697      PMCID： PMC3029247          DOI： 10.1136/bcr.08.2008.0654

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  16 in total

1.  Chronic chloroquine treatment enhances insulin release in rats.

Authors:  K A Asamoah; D A Robb; B L Furman
Journal:  Diabetes Res Clin Pract       Date:  1990-07       Impact factor: 5.602

2.  Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-04

3.  Is there a role for chloroquine treatment in diabetes? A three case report.

Authors:  A Quatraro; G Consoli; A Ceriello; D Giugliano
Journal:  Diabete Metab       Date:  1988 Sep-Oct

4.  Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus.

Authors:  J K Powrie; G D Smith; F Shojaee-Moradie; P H Sönksen; R H Jones
Journal:  Am J Physiol       Date:  1991-06

5.  The inhibition of gluconeogenesis by chloroquine contributes to its hypoglycaemic action.

Authors:  R Jarzyna; A Kiersztan; O Lisowa; J Bryła
Journal:  Eur J Pharmacol       Date:  2001-10-12       Impact factor: 4.432

6.  Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids.

Authors:  D J Wallace; A L Metzger; V J Stecher; B A Turnbull; P A Kern
Journal:  Am J Med       Date:  1990-09       Impact factor: 4.965

7.  In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance.

Authors:  B R Blazar; C B Whitley; A E Kitabchi; M Y Tsai; J Santiago; N White; F B Stentz; D M Brown
Journal:  Diabetes       Date:  1984-12       Impact factor: 9.461

8.  Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older.

Authors:  Julia F Simard; Murray A Mittleman
Journal:  J Rheumatol       Date:  2007-12-15       Impact factor: 4.666

9.  The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial.

Authors:  Hertzel C Gerstein; Kevin E Thorpe; D Wayne Taylor; R Brian Haynes
Journal:  Diabetes Res Clin Pract       Date:  2002-03       Impact factor: 5.602

10.  Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.

Authors:  Mary Chester M Wasko; Helen B Hubert; Vijaya Bharathi Lingala; Jennifer R Elliott; Michael E Luggen; James F Fries; Michael M Ward
Journal:  JAMA       Date:  2007-07-11       Impact factor: 56.272
View more
  4 in total

Review 1.  A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.

Authors:  Mirella P Hage; Marwa R Al-Badri; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-08       Impact factor: 3.565

Review 2.  Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.

Authors:  Ahmed El-Solia; Khalid Al-Otaibi; Abdullah K Ai-Hwiesh
Journal:  BMJ Case Rep       Date:  2018-04-18

Review 3.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

4.  Coronary artery disease (CAD) risk factor analysis in an age-stratified hospital population with systemic lupus erythematosus (SLE).

Authors:  Dennis J Levinson; Ashraf Abugroun; Hussein Daoud; Manar Abdel-Rahman
Journal:  Int J Cardiol Hypertens       Date:  2020-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.